Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Healthy Volunteer

What is this?
A volunteer subject with no known significant health problems who participates in research to test a new drug, device or intervention. These volunteers are recruited to serve as controls for patient groups. Healthy volunteers receive the same test, procedure, or drug the patient group receives.

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 231-240 of 3405 for cancer

Edit search filters
  1. Etigilimab and Nivolumab in Subjects With Locally Advanced or Metastatic Tumors

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  2. Study of XL092 in Combination With Immuno-Oncology Agents in Subjects With Solid Tumors

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  3. Olaparib and Cediranib Maleate in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

    Rochester, MN

  4. Sym021 in Combination with Either Sym022 or Sym023 or Sym023 and Irinotecan in Patients with Advanced Biliary Tract Carcinomas

    Rochester, MN

  5. A Study to Assess the Safety and Dose Escalation of Pegtomarginase (PT01) for Subjects with Advanced Malignancies

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  6. Dose Escalation and Expansion Study of GSK525762 in Combination With Fulvestrant in Subjects With Estrogen Receptor Positive (ER+) Breast Cancer

    Scottsdale/Phoenix, AZ, Rochester, MN, Jacksonville, FL

  7. Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations

    Scottsdale/Phoenix, AZ, Rochester, MN

  8. A Study to Evaluate KIN-3248 in Participants With Advanced Tumors Harboring FGFR2 and//or FGFR3 Gene Alterations

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  9. A Study of 177Lu-FAP-2286 in Advanced Solid Tumors (LuMIERE)

    Rochester, MN, Jacksonville, FL

  10. Olaparib Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy.

    Rochester, MN

.

Mayo Clinic Footer